Compare DexCom, Inc. (DXCM) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? DexCom, Inc. trades at $84.02 (market cap $31.86B), while iShares 20 Plus Year Treasury Bond ETF trades at $77.9 (market cap $47.61B). The key difference: iShares 20 Plus Year Treasury Bond ETF is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and iShares 20 Plus Year Treasury Bond ETF for 83 Days on average.
| DXCM | TLT | |
|---|---|---|
Market Cap | $31.86B | $47.61B |
Volume | 3,607,070 | 49,263,490 |
Sector | Health | Fixed Income |
52-Week High | $92.34 | $92.06 |
52-Week Low | $54.84 | $77.11 |
Typical Hold Time | 62 Days | 83 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.71 with a slight 0.73% daily gain amid a challenging bond market environment. The technical picture remains bearish with moving averages signaling continued pressure, while oscillators show neutral momentum. Recent news highlights Treasury yields reaching multi-decade highs, with the fund down 11% year-to-date and 46% over five years as investors face a new era of higher interest rates.
The outlook for TLT remains pressured by rising interest rates and inflation concerns, though current yields near 5.3% offer attractive income potential. Key risks include further Fed tightening and economic uncertainty, while potential catalysts could emerge from any moderation in inflation or economic slowdown that might prompt rate cuts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
